Cigarette-smoke-induced atherogenic lipid profiles in plasma and vascular tissue of apolipoprotein E-deficient mice are attenuated by smoking cessation

Atherosclerosis

Volumn 229, Issue 1, 2013, Pages 86-93

  Lietz, Michael ^a   Berges, An ^b   Lebrun, Stefan ^b   Meurrens, Kris ^b   Steffen, Yvonne ^b   Stolle, Katrin ^a   Schueller, Jutta ^a   Boue, Stephanie ^b   Vuillaume, Grégory ^b   Vanscheeuwijck, Patrick ^b   Moehring, Michaela ^b   Schlage, Walter ^a   De Leon, Hector ^b   Hoeng, Julia ^b   Peitsch, Manuel ^b  

^a Philip Morris Research Laboratories GmbH   (Germany)

^b PHILIP MORRIS PRODUCTS S A   (Switzerland)

Author keywords

Aortic plaque; ApoE mice; Atherosclerosis; Complex lipids; Glycosphingolipids; Lipidomics; Smoking cessation; Sphingomyelins; Vascular lipids

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL ESTER; CIGARETTE SMOKE; GLYCOSPHINGOLIPID; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; SPHINGOMYELIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA ARCH; ARTICLE; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; SMOKING CESSATION; VASCULAR TISSUE;

ANIMALS; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL; DISEASE MODELS, ANIMAL; FEMALE; GLYCOSPHINGOLIPIDS; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; MICE; MICE, KNOCKOUT; SMOKING; SMOKING CESSATION; SPHINGOMYELINS;

EID: 84879409128     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.03.036     Document Type: Article

References (29)

1. Price J.F., Mowbray P.I., Lee A.J., et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. European Heart Journal 1999, 20:344-353.
2. Surgeon_General Cardiovascular diseases. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General 2010, 351-434. The Surgeon General, Atlanta (GA). Multiple (Ed.).
3. Bakhru A., Erlinger T.P. Smoking cessation and cardiovascular disease risk factors: results from the Third National Health and Nutrition Examination Survey. PLoS Medicine 2005, 2:e160.
4. Gepner A.D., Piper M.E., Johnson H.M., et al. Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. American Heart Journal 2011, 161:145-151.
5. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010, 210:353-361.
6. Ekroos K., Janis M., Tarasov K., et al. Lipidomics: a tool for studies of atherosclerosis. Current Atherosclerosis Reports 2010, 12:273-281.
7. Nakashima Y., Plump A.S., Raines E.W., et al. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Ateriosclerosis and Thrombosis 1994, 14:133-140.
8. Boue S., Tarasov K., Minna J., et al. Modulation of atherogenic lipidome by cigarette smoke in apolipoprotein E-deficient mice. Atherosclerosis 2012.
9. Terpstra P.M., Teredesai A., Vanscheeuwijck P.M., et al. Toxicological evaluation of an electrically heated cigarette. Part 4: subchronic inhalation toxicology. Journal of Applied Toxicology 2003, 23:349-362.
10. Health Canada Determination of "tar", nicotine and carbon monoxide in mainstream tobacco smoke - official method. In, Ottawa 1999.
11. Chiolero A., Faeh D., Paccaud F., et al. Consequences of smoking for body weight, body fat distribution, and insulin resistance. The American Journal of Clinical Nutrition 2008, 87:801-809.
12. Willett W.C., Green A., Stampfer M.J., et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. The New England Journal of Medicine 1987, 317:1303-1309.
13. -/- model: 12-month exposure to cigarette mainstream smoke combined with high-cholesterol/fat diet. Atherosclerosis 2009, 205:135-143.
14. Nishina P.M., Wang J., Toyofuku W., et al. Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. Lipids 1993, 28:599-605.
15. Chelland Campbell S., Moffatt R.J., Stamford B.A. Smoking and smoking cessation - the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis 2008, 201:225-235.
16. Conklin D.J., Barski O.A., Lesgards J.F., et al. Acrolein consumption induces systemic dyslipidemia and lipoprotein modification. Toxicology and Applied Pharmacology 2010, 243:1-12.
17. Plump A.S., Breslow J.L. Apolipoprotein E and the apolipoprotein E-deficient mouse. Annual Review of Nutrition 1995, 15:495-518.
18. Ha Y.C., Barter P.J. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comparative Biochemistry and Physiology-Part B 1982, 71:265-269.
19. Fan Y., Shi F., Liu J., et al. Selective reduction in the sphingomyelin content of atherogenic lipoproteins inhibits their retention in murine aortas and the subsequent development of atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30:2114-2120.
20. Chatterjee S., Bhunia A.K., Snowden A., et al. Oxidized low density lipoproteins stimulate galactosyltransferase activity, ras activation, p44 mitogen activated protein kinase and c-fos expression in aortic smooth muscle cells. Glycobiology 1997, 7:703-710.
21. Bhunia A.K., Han H., Snowden A., et al. Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells. The Journal of Biological Chemistry 1997, 272:15642-15649.
22. Portman O.W., Alexander M. Lysophosphatidylcholine concentrations and metabolism in aortic intima plus inner media: effect of nutritionally induced atherosclerosis. Journal of Lipid Research 1969, 10:158-165.
23. Quinn M.T., Parthasarathy S., Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proceedings of the National Academy of Sciences of The United States of America 1988, 85:2805-2809.
24. Blajecka K., Borgstrom A., Arcaro A. Phosphatidylinositol 3-kinase isoforms as novel drug targets. Current Drug Targets 2011, 12:1056-1081.
25. Hojjati M.R., Li Z., Zhou H., et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. The Journal of Biological Chemistry 2005, 280:10284-10289.
26. Keul P., Tolle M., Lucke S., et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:607-613.
27. Klingenberg R., Nofer J.R., Rudling M., et al. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:2392-2399.
28. Stegemann C., Drozdov I., Shalhoub J., et al. Comparative lipidomics profiling of human atherosclerotic plaques. Circulation, Cardiovascular Genetics 2011, 4:232-242.
29. Ambrose J.A., Barua R.S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. Journal of the American College of Cardiology 2004, 43:1731-1737.